Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs
The authors propose extending initial solvent screening for a single-solvent system to the cocktail solvent screening of binary and ternary solvent mixtures.


Pharmaceutical Technology
Volume 32, Issue 1

11. T. Lee and M.S. Lin, "Sublimation Point Depression of Tris(8-hydroxyquinoline) aluminum (III) (Alq3) by Crystal Engineering," Cryst. Growth Des. 7 (9), 1803–1810 (2007).

12. Y. Kawashima, M. Okumura and H. Takenaka, "Spherical Crystallization: Direct Spherical Agglomeration of Salicylic Acid Crystals During Crystallization," Science 216 (4550), 1127–1128 (1982).

13. R.A. Granberg and .C. Rasmuson, "Crystal Growth Rates of Paracetamol in Mixtures of Water + Acetone + Toluene," AIChE Journal 51 (9), 2441–2456 (2005).

14. M.L. Peterson et al., "Iterative High-Throughput Polymorphism Studies on Acetaminophen and an Experimentally Derived Structure for Form III," J. Am. Chem. Soc. 124 (37), 10958–10959 (2002).

15. J.E. Anderson et al., "Determination of the Onset of Crystallization of N1-2-(thiazolyl)sulfanilamide (sulfathiazole) by UV–Vis and Calorimetry Using an Automated Reaction Platform; Subsequent Characterization of Polymorphic Forms Using Dispersive Raman Spectroscopy," Spectrochimica Acta Part A 57 (9), 1793–1808 (2001).

16. S. Khoshkhoo and J. Anwar, "Crystallization of Polymorphs: the Effect of Solvent," J. Phys. D: Appl. Phys. 26 (8B), B90–B93 (1993).

17. J. Anwar, S.E. Tarling, and P. Barnes, "Polymorphism of Sulfathiazole," J. Pharm Sci. 78 (4), 337–342 (1989).

18. D.C. Grove and G. Keenan, "The Dimorphism of Sulfathiazole," J. Am. Chem. Soc. 63 (1), 97–99 (1941).

19. A.L. Bingham et al., "Over One Hundred Solvates of Sulfathiazole," Chem. Commun. (7), 603–604 (2001).

20. E. Tedesco, D. Giron, and S. Pfeffer, "Crystal Structure Elucidation and Morphology Study of Pharmaceuticals in Development," Cryst. Eng. Comm. 4 (67), 393–400 (2002).

21. N. Blagden and R.J. Davey, "Review: Polymorph Selection—Challenges for the Future?" Cryst. Growth Des. 3 (6), 873–885 (2003).

22. D. Winn and M.F. Doherty, "Modeling Crystal Shapes of Organic Materials Grown from Solution," AIChE J. 46 (7), 1348–1367 (2000).

23. S. Byrn, K. Morris, and S. Comella, "Reducing Time to Market with a Science-Based Product," Pharm. Technol. Outsourcing Resources for the Pharmaceutical Industry supplement, 46–56 (2005).

24. T. Lee, C.S. Kuo, and Y.H. Chen, "Solubility, Polymorphism, Crystallinity, and Crystal Acetaminophen and Ibuprofen by Initial Solvent Screening," Pharm. Technol. 30 (10), 72–92 (2006).

25. N.G. Anderson, Practical Process Research and Development , (Academic Press, New York, 2000), pp. 81–111.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here